Pulsenmore and Clalit launch at-home follicular monitoring service for IVF and fertility preservation
Improving patient experience while preserving clinical oversight
At-home ultrasound company Pulsenmore has signed a new commercial agreement with Clalit Health Services to launch what the companies describe as the first at-home follicular monitoring service for women undergoing IVF and fertility preservation.
The agreement follows an 18-month pilot and is potentially valued at approximately $4.5m over five years. The service will be deployed through Beilinson NEXT, the virtual hospital operated by Beilinson Medical Center in partnership with Clalit. Ramp-up is expected to begin in the coming weeks.
At the centre of the programme is Pulsenmore FC, a patient-operated home ultrasound device designed to enable women to perform follicular monitoring scans from home. Using step-by-step guidance in a mobile app, eligible patients can conduct transvaginal scans themselves, with images transmitted securely to a specialist clinical team for interpretation and oversight.
Reducing the need for repeated in-clinic visits
Follicular monitoring is a core component of IVF and fertility preservation, requiring repeated ultrasound scans to assess follicle development and endometrial thickness and to time trigger injections and egg retrieval. In standard care, this often means frequent clinic visits over short periods of time, creating logistical, emotional, and financial burdens that disproportionately fall on women.
Pulsenmore and Clalit said the new service is intended to reduce the need for repeated in-clinic visits while maintaining clinical standards. Under the agreement, both organisations will be able to market Pulsenmore FC directly to patients.
Pulsenmore previously reported results from a controlled clinical study conducted at Beilinson Medical Center and published in June 2025, showing high concordance between at-home measurements and in-clinic assessments, alongside a strong safety profile.
“We believe this agreement represents a global breakthrough in how fertility care can be delivered,” said Dr Elazar Sonnenschein, founder and CEO of Pulsenmore.
“We are enabling a new model of care that respects patients’ time, privacy, and daily lives, while maintaining clinical oversight.”
Clalit’s CEO, Dr Eytan Wirtheim, described the launch as aligned with the organisation’s broader strategy to shift appropriate services out of hospital settings and into the home.
“Any medical service that can be provided to patients from the comfort and calm of their homes, instead of requiring visits to hospital clinics, will be offered in this way—provided it can be delivered at the same level of quality as in the hospital setting,” Wirtheim said.
He added that fertility treatment, with its physical and emotional demands, was particularly well suited to this model.
Initial phase plans
The initial phase will involve a limited group of women, with the expectation that the service could later be expanded more broadly across Clalit’s member base. Clalit serves close to five million people and operates an integrated network of community clinics and hospitals across Israel.
Pulsenmore FC is currently approved for commercial use in Israel. The company did not disclose whether it plans to seek regulatory clearance for the follicular monitoring product in other markets.
The agreement builds on an existing relationship between the two organisations. Pulsenmore already supplies Clalit with Pulsenmore ES, a physician-supervised home prenatal ultrasound solution. In October 2024, the company signed a binding agreement with Clalit to supply an additional 25,000 Pulsenmore ES units over five years, supported by Pulsenmore’s hardware, secure image transmission, and clinical review infrastructure. Pulsenmore ES has since received FDA De Novo authorisation in the US.
The expansion into fertility care comes amid growing interest in remote and hybrid models for women’s health services, particularly in areas that require frequent monitoring over compressed timeframes. IVF and fertility preservation cycles can involve multiple clinic visits per week, making access especially challenging for patients balancing work, caregiving responsibilities, or long travel distances.